跳至主要内容
临床试验/NCT05766163
NCT05766163Unknown不适用

Comparative Evaluation of New Surgical Robotic Platforms for the Radical Prostatectomy Procedure

Azienda Ospedaliera Universitaria Integrata Verona1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2023年3月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
150
试验地点
1
主要终点
Number of participants with postoperative complications

研究概览

简要总结

The object of this exploratory clinical trial is to evaluate post-operative complications in a population that underwent Robotic Assisted Radical Prostatectomy (RARP) made with multiple platforms:

  • DaVinci;
  • Hugo;
  • Versius.

The questions it aims to answer are:

  • Does the estimation of the post-operative complications suggest something?
  • Are differences (intra-operative, post-operative, oncological, functional, technical, and economic) among the three intervention approaches observable?

Participants will be invited to fill out questionnaires and join one of these three groups:

  1. surgery with the daVinci platform;
  2. surgery with the Hugo platform;
  3. surgery with the Versius platform.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Age > 18 and < 90 years;
  • •Organ-localized prostate cancer with a surgical indication of radical prostatectomy;
  • •Informed consent provided.

排除标准

  • •Age < 18 and > 90 years;
  • •Contraindication to radical prostatectomy procedure;
  • •Non-organ confined prostate cancer;
  • •Refusal to participate.

研究组 & 干预措施

DaVinci system

Active Comparator

Robot-assisted radical prostatectomy is carried out through daVinci platform.

干预措施: DaVinci RARP (Device)

Hugo system

Experimental

Robot-assisted radical prostatectomy is carried out through Hugo platform.

干预措施: Hugo RARP (Device)

Versius system

Experimental

Robot-assisted radical prostatectomy is carried out through Versius platform.

干预措施: Versius RARP (Device)

结局指标

主要结局

Number of participants with postoperative complications

时间窗: Over the 4 days post surgery

Overall postoperative complications (% score \>0) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

Number of participants with moderate to major postoperative complications

时间窗: Over the 4 days post surgery

Moderate to major complications (% score \>=2) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

Number of participants with major postoperative complications

时间窗: Over the 4 days post surgery

Major complications (% score \>=3) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

次要结局

  • Overall duration of the surgery(Intraoperative)
  • Number and type of intraoperative complications(Intraoperative)
  • Time taken for platform-related technical steps(From the room setting, through surgical procedure until postoperative room restoration for each of expected 150 surgeries (through study completion: an average of 1 year))
  • Anesthesia, Lymphadenectomy, Prostatectomy(Entrance of patient into operating room until completion of surgery)
  • Postoperative hospitalization(From the surgery day up to 10 days postoperative)
  • Possible malfunction of the platform(Intraoperative)
  • Positive Surgical Margin(Up to 2 weeks postoperative (during histological analysis))
  • Lymph nodes resection(Intraoperative)
  • Urinary, sexual, and intestinal function assessment(Preoperative and follow-up (1, 3 and 6 months))
  • Procedure-related costs(From surgical procedure to the end of follow-up period (6 months))
  • Estimated Blood Loss(Intraoperative)
  • Postoperative pain(1-4 days postoperative)
  • Prostate Specific Antigen (PSA)(1 month follow-up)
  • Quality of Life Evaluation(Preoperative and follow-up at 1, 3 and 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alessandro Antonelli, MD, Prof

Director of Urology Unit

Azienda Ospedaliera Universitaria Integrata Verona

研究点 (1)

Loading locations...

相似试验